Cost-of-illness analysis and regression modeling in cystic
fibrosis: a retrospective prevalence-based study

J 2017

Cost-of-illness analysis and regression modeling in cystic fibrosis: a retrospective prevalence-based study

MLČOCH, Tomáš, Jiří KLIMEŠ, Libor FILA, Věra VÁVROVÁ, Veronika SKALICKÁ et. al.

Basic information

Original name

Cost-of-illness analysis and regression modeling in cystic fibrosis: a retrospective prevalence-based study

Authors

MLČOCH, Tomáš (203 Czech Republic), Jiří KLIMEŠ (203 Czech Republic), Libor FILA (203 Czech Republic), Věra VÁVROVÁ (203 Czech Republic), Veronika SKALICKÁ (203 Czech Republic), Marek TURNOVEC (203 Czech Republic), Veronika KRULIŠOVÁ (203 Czech Republic), Jitka JIRČÍKOVÁ (203 Czech Republic), Dana ZEMKOVÁ (203 Czech Republic), Klára VILIMOVSKÁ DĚDEČKOVÁ (203 Czech Republic), Alena BÍLKOVÁ (203 Czech Republic), Vladimíra FRÜHAUFOVÁ (203 Czech Republic), Lukáš HOMOLA (203 Czech Republic, guarantor, belonging to the institution), Zuzana FRIEDMANNOVÁ (203 Czech Republic), Radovan DRNEK (203 Czech Republic), Pavel DŘEVÍNEK (203 Czech Republic), Tomáš DOLEŽAL (203 Czech Republic) and Milan MACEK (203 Czech Republic)

Edition

EUROPEAN JOURNAL OF HEALTH ECONOMICS, NEW YORK, SPRINGER, 2017, 1618-7598

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

50200 5.2 Economics and Business

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

Impact factor

Impact factor: 2.601

RIV identification code

RIV/00216224:14110/17:00096876

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1007/s10198-015-0759-9

UT WoS

000392437100007

Keywords in English

Cystic fibrosis; Cost-of-illness; Disease severity; Health care costs; FEV1; Generalized linear model

Abstract

V originále

Economic data pertaining to cystic fibrosis (CF), is limited in Europe generally, and completely lacking in Central and Eastern Europe. We performed an analysis of all direct costs associated with CF relative to key disease features and laboratory examinations. A retrospective prevalence-based cost-of-illness (COI) study was performed in a representative cohort of 242 CF patients in the Czech Republic, which represents about 65 % of all Czech CF patients. Medical records and invoices to health insurance companies for reference year 2010 were analyzed. The mean total health care costs were a,notsign14,486 per patient, with the majority of the costs going towards medicinal products and devices (a,notsign10,321). Medical procedures (a,notsign2676) and inpatient care (a,notsign1829) represented a much smaller percentage of costs. A generalized linear model showed that the strongest cost drivers, for all cost categories, were associated with patient age and lung disease severity (assessed using the FEV1 spirometric parameter), when compounded by chronic Pseudomonas aeruginosa airway infections. Specifically, maximum total costs are around the age 16 years; a FEV1 increase of 1 % point represented a cost decrease of: 0.9 % (medicinal products), 1.7 % (total costs), 2.8 % (procedures) and 7.0 % (inpatient care). COI analysis and regression modeling using the most recent data available can provide a better understanding of the overall economic CF burden. A comparison of our results with other methodologically similar studies demonstrates that although overall costs may differ, FEV1 can nonetheless be utilized as a generally transferrable indicator of the relative economic impact of CF.

Citovat

MLČOCH, Tomáš, Jiří KLIMEŠ, Libor FILA, Věra VÁVROVÁ, Veronika SKALICKÁ, Marek TURNOVEC, Veronika KRULIŠOVÁ, Jitka JIRČÍKOVÁ, Dana ZEMKOVÁ, Klára VILIMOVSKÁ DĚDEČKOVÁ, Alena BÍLKOVÁ, Vladimíra FRÜHAUFOVÁ, Lukáš HOMOLA, Zuzana FRIEDMANNOVÁ, Radovan DRNEK, Pavel DŘEVÍNEK, Tomáš DOLEŽAL and Milan MACEK. Cost-of-illness analysis and regression modeling in cystic fibrosis: a retrospective prevalence-based study. EUROPEAN JOURNAL OF HEALTH ECONOMICS. NEW YORK: SPRINGER, 2017, vol. 18, No 1, p. 73-82. ISSN 1618-7598. Available from: https://dx.doi.org/10.1007/s10198-015-0759-9.

@article{1382080,
   author = {Mlčoch, Tomáš and Klimeš, Jiří and Fila, Libor and Vávrová, Věra and Skalická, Veronika and Turnovec, Marek and Krulišová, Veronika and Jirčíková, Jitka and Zemková, Dana and Vilimovská Dědečková, Klára and Bílková, Alena and Frühaufová, Vladimíra and Homola, Lukáš and Friedmannová, Zuzana and Drnek, Radovan and Dřevínek, Pavel and Doležal, Tomáš and Macek, Milan},
   article_location = {NEW YORK},
   article_number = {1},
   doi = {http://dx.doi.org/10.1007/s10198-015-0759-9},
   keywords = {Cystic fibrosis; Cost-of-illness; Disease severity; Health care costs; FEV1; Generalized linear model},
   language = {eng},
   issn = {1618-7598},
   journal = {EUROPEAN JOURNAL OF HEALTH ECONOMICS},
   title = {Cost-of-illness analysis and regression modeling in cystic fibrosis: a retrospective prevalence-based study},
   volume = {18},
   year = {2017}
}

TY  - JOUR
ID  - 1382080
AU  - Mlčoch, Tomáš - Klimeš, Jiří - Fila, Libor - Vávrová, Věra - Skalická, Veronika - Turnovec, Marek - Krulišová, Veronika - Jirčíková, Jitka - Zemková, Dana - Vilimovská Dědečková, Klára - Bílková, Alena - Frühaufová, Vladimíra - Homola, Lukáš - Friedmannová, Zuzana - Drnek, Radovan - Dřevínek, Pavel - Doležal, Tomáš - Macek, Milan
PY  - 2017
TI  - Cost-of-illness analysis and regression modeling in cystic fibrosis: a retrospective prevalence-based study
JF  - EUROPEAN JOURNAL OF HEALTH ECONOMICS
VL  - 18
IS  - 1
SP  - 73-82
EP  - 73-82
PB  - SPRINGER
SN  - 16187598
KW  - Cystic fibrosis
KW  - Cost-of-illness
KW  - Disease severity
KW  - Health care costs
KW  - FEV1
KW  - Generalized linear model
N2  - Economic data pertaining to cystic fibrosis (CF), is limited in Europe generally, and completely lacking in Central and Eastern Europe. We performed an analysis of all direct costs associated with CF relative to key disease features and laboratory examinations. A retrospective prevalence-based cost-of-illness (COI) study was performed in a representative cohort of 242 CF patients in the Czech Republic, which represents about 65 % of all Czech CF patients. Medical records and invoices to health insurance companies for reference year 2010 were analyzed. The mean total health care costs were a,notsign14,486 per patient, with the majority of the costs going towards medicinal products and devices (a,notsign10,321). Medical procedures (a,notsign2676) and inpatient care (a,notsign1829) represented a much smaller percentage of costs. A generalized linear model showed that the strongest cost drivers, for all cost categories, were associated with patient age and lung disease severity (assessed using the FEV1 spirometric parameter), when compounded by chronic Pseudomonas aeruginosa airway infections. Specifically, maximum total costs are around the age 16 years; a FEV1 increase of 1 % point represented a cost decrease of: 0.9 % (medicinal products), 1.7 % (total costs), 2.8 % (procedures) and 7.0 % (inpatient care). COI analysis and regression modeling using the most recent data available can provide a better understanding of the overall economic CF burden. A comparison of our results with other methodologically similar studies demonstrates that although overall costs may differ, FEV1 can nonetheless be utilized as a generally transferrable indicator of the relative economic impact of CF.
ER  -

MLČOCH, Tomáš, Jiří KLIMEŠ, Libor FILA, Věra VÁVROVÁ, Veronika SKALICKÁ, Marek TURNOVEC, Veronika KRULIŠOVÁ, Jitka JIRČÍKOVÁ, Dana ZEMKOVÁ, Klára VILIMOVSKÁ DĚDEČKOVÁ, Alena BÍLKOVÁ, Vladimíra FRÜHAUFOVÁ, Lukáš HOMOLA, Zuzana FRIEDMANNOVÁ, Radovan DRNEK, Pavel DŘEVÍNEK, Tomáš DOLEŽAL and Milan MACEK. Cost-of-illness analysis and regression modeling in cystic fibrosis: a retrospective prevalence-based study. \textit{EUROPEAN JOURNAL OF HEALTH ECONOMICS}. NEW YORK: SPRINGER, 2017, vol.~18, No~1, p.~73-82. ISSN~1618-7598. Available from: https://dx.doi.org/10.1007/s10198-015-0759-9.

Detailed Information on Publication Record